Assessing Legend Biotech: Insights From 15 Financial Analysts
Assessing Legend Biotech: Insights From 15 Financial Analysts
評估傳奇生物：來自15位金融分析師的見解
Legend Biotech (NASDAQ:LEGN) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
在過去的季度中，傳奇生物（納斯達克股票代碼: LEGN）接受了15位分析師的分析，呈現出從看好到看淡的各種觀點。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您將找到他們最近的評級摘要，揭示了過去30天內情緒的變化，並將它們與前幾個月進行比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $80.67, a high estimate of $90.00, and a low estimate of $60.00. A decline of 0.81% from the prior average price target is evident in the current average.
分析師通過其12個月的價格目標給出更深入的洞見，顯示出平均目標爲80.67美元，最高估值爲90.00美元，最低估值爲60.00美元。從先前的平均價格目標下降了0.81%，可見當前的平均價格目標。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀：深入分析
A comprehensive examination of...
通過對最...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。